Navigation Links
Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)
Date:9/26/2007

months. In addition, 11 of 28 patients (39%) experienced stable disease (duration 1.2+ to 12.6+ months). Objective response was assessed radiologically after every two cycles (8 weeks) of therapy. A partial response is characterized as a decrease in size by 30% of the sum of the longest diameters of target lesions, the absence of progression of all non-target lesions and no new lesions.

Grade 3 and 4 neutropenia occurred in 8 (28%) and 15 (52%) patients. Grade 3 and 4 thrombocytopenia occurred in 8 (28%) and 2 (7%) patients. Five patients (18%) had a glufosfamide-related serious adverse event (SAE), which included renal tubular acidosis (RTA) with renal failure (2 patients), RTA alone, vomiting or nausea. Three patients died from an SAE unrelated to glufosfamide. Another patient developed an SAE of renal failure after hypotension associated with pulmonary embolus. The creatinine clearance (CrCL) fell below 60 mL/min in 10 of 27 (37%) patients with CrCL greater than or equal to 60 at baseline.

These data indicate that glufosfamide plus gemcitabine may benefit patients with chemotherapy nave pancreatic adenocarcinoma. Hematologic and renal toxicity may be greater than would be expected with either agent alone although the small numbers preclude definitive conclusions. No unanticipated adverse events based on previous experience with glufosfamide were observed.

The Phase 2 poster is available on the Threshold website at http://investor.thresholdpharm.com/calendar.cfm.

About Glufosfamide

Glufosfamide combines the active part of ifosfamide, a member of a widely used class of chemotherapy drugs known as "alkylators", with a glucose molecule. Because of its glucose component and a tumor cell's increased need for glucose, glufosfamide may be preferentially transported into tumors compared to most normal tissues. Inside cells, the linkage between glucose and the alkylat
'/>"/>

SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013   Shareholder rights attorneys  at ... Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint ... Massachusetts .  The complaint alleges that ... Exchange Act of 1934 (the "Exchange Act") between January ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
(Date:5/17/2013)... Ill. , May 17, 2013  Sony Biotechnology ... Sony SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting ... which will be held at the San ... Diego, California , from May 20 - 22.  ... second analytical system, incorporating commercial audio-visual technologies into new ...
(Date:5/17/2013)... -- Research explores data on treatments ...   to   be presented Shire ... global specialty biopharmaceutical company, announces that it will present ... Psychiatric Association (APA) 166th Annual Meeting in ... presented represent Shire,s ongoing commitment to the clinical research ...
Breaking Medicine Technology:Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... WIRE)--May 17, 2007 - BioLineRx Ltd. (TASE:,BLRX), ... abstracts containing data from its successfully completed,phase ... class GABA-enhanced,antipsychotic for the treatment of schizophrenia, ... leading scientific,conferences. The data will be presented ...
... Symposium on,Myelodysplastic Syndromes, TAMPA, Fla., May 17, 2007 ... II trial evaluating Revlimid in patients with,an incurable ... today by Dr. Alan List, from the H. ... 9th International,Symposium on MDS currently taking place in ...
Cached Medicine Technology:BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 2BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 3Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3
(Date:5/19/2013)... Boca Raton, FL (PRWEB) May 19, 2013 ... have launched the website YazSideEffects.com in a concerted effort ... effects of the combination birth control drugs Yaz, Yasmin ... website offers a wealth of information on the notorious ... about lawsuits against Bayer Pharmaceuticals. , Yaz, Yasmin ...
(Date:5/18/2013)... Colorado (PRWEB) May 18, 2013 Daily Gossip ... of a new review on their page. John Colston, Daily ... readers to Shaun Hadsall’s revolutionizing 14-Day Rapid Fat Loss ... to sustain that carbs are healthy at a time when ... away from highly caloric products. , The diet is ...
(Date:5/18/2013)... Also known as bariatric surgery ... loss surgery that guarantees patients long-term weight loss. Dr. ... to give readers a brief tutorial on this revolutionary ... at New York City’s Mount Sinai School of Medicine. ... a fellowship in Minimally Invasive Bariatric Surgery. He has ...
(Date:5/18/2013)... (HealthDay News) -- Children who swallow high-powered magnets often ... objects, according to a new study. The researchers, ... Orleans, found that more than 79 percent of children ... or an endoscopic procedure, in which a tube containing ... 21 percent of these cases can be treated through ...
(Date:5/18/2013)... FL (May 18, 2013) There are significant ... commonly used to diagnose or treat gastrointestinal problems, ... (DDW). , A study by New York ... more objective testing may substantially reduce the cost ... Although GERD is believed to affect nearly 25 ...
Breaking Medicine News(10 mins):Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2
... the condition appear to have longer soft palates, research shows ... the breathing disturbance known as obstructive sleep apnea have soft ... people without the condition, researchers report. , The soft palate ... the mouth. , A team at the Seoul National University ...
... Feb. 20 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... has entered into a new, three year, exclusive distribution ... based in Kfar Saba, Israel, for the distribution of ...
... clot-busting drug delivered directly to the brain , , FRIDAY, ... used for years to open blocked coronary blood vessels, ... vessels clogged from strokes, according to new research. , ... treatment or prevention as well, a panel of researchers ...
... hemodialysis (which removes large toxins) reduces the risk of ... (CKD), according to a study appearing in the March ... Society Nephrology (JASN). The results suggest that this ... and those with diabetes. , In patients with CKD, ...
... The hospital services department at Northwest Kidney Centers ... for health care staffing services from The Joint ... is the nation,s oldest and largest standards-setting and ... stand-alone dialysis centers, NKC has a 55-member hospital ...
... th , 2009 in London SOUTHFIELD, ... middle market investment banking firm, is pleased to announce ... and formed a partnership with Robin Young to present ... spinal implant and instrumentation companies. The Spine Technology ...
Cached Medicine News:Health News:Anatomy May Help Identify Sleep Apnea 2Health News:Misonix Announces New Distribution Agreement for Israel 2Health News:Misonix Announces New Distribution Agreement for Israel 3Health News:New Advances May Treat Stroke Faster, Better 2Health News:New Advances May Treat Stroke Faster, Better 3Health News:New Advances May Treat Stroke Faster, Better 4Health News:High-flux hemodialysis prolongs survival in many patients with CKD 2Health News:Northwest Kidney Centers Hospital Services Department Awarded Joint Commission Certification 2Health News:UPDATE: P&M Corporate Finance Announces Partnership with Robin Young to Present the Fifth Annual Spine Technology Summit 2
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... The 5702 is a heavy-duty, stainless ... for the special needs of bariatric patients. ... handrail assure ease and security. The scale ... weighing, allowing you to weigh a continuous ...
... Endo-PAT2000 is a simple and easy to ... PAT signal is recorded using Itamar Medical's ... is analyzed automatically using proprietary advanced Digital ... within seconds of completing the test. The ...
... synthesized by the parathyroid glands [1,2] ... extracellular calcium concentrations. PTH prevents hypocalcemia ... calcium excretion by the kidney. Following ... is rapidly degraded into 4 fragments: ...
Medicine Products: